Concanamycin A
Based on 28 publication(s) in Google Scholar
Concanamycin A (Folimycin; Antibiotic X 4357B) is a macrolide antibiotic, a vacuolar type H+-ATPase (V-ATPase) inhibitor. Concanamycin A is also an inhibitor of lysosomal acidification, can be used to T cell-mediated inflammation research-.
For research use only. We do not sell to patients.
- Purity: 99.84%
- CAS No.: 80890-47-7
- Formula: C46H75NO14
- Molecular Weight:866.09
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Concanamycin A
More- Nat Nanotechnol. 2025 Feb;20(2):296-302. [Abstract]
- Cell Res. 2026 Jul;36(7):475-498. [Abstract]
- Mol Cell. 2025 Sep 4;85(17):3333-3342.e4. [Abstract]
- Nat Commun. 2025 Jul 18;16(1):6621. [Abstract]
- Autophagy. 2023 Jun;19(6):1745-1763. [Abstract]
- Adv Sci (Weinh). 2026 Apr;13(24):e20627. [Abstract]
- Adv Sci (Weinh). 2026 Jan 20:e16355. [Abstract]
- Adv Sci (Weinh). 2025 Dec 2:e04665. [Abstract]
- Nat Plants. 2025 Sep 12. [Abstract]
- Biomaterials. 2025 Dec 18:329:123925. [Abstract]
- Sci Adv. 2023 Oct 13;9(41):eadh1134. [Abstract]
- Cell Death Dis. 2023 Aug 29;14(8):571. [Abstract]
- Dev Cell. 2026 Feb 17:S1534-5807(26)00037-7. [Abstract]
- Dev Cell. 2025 Jul 9:S1534-5807(25)00402-2. [Abstract]
- Free Radic Biol Med. 2025 Aug 16:236:204-219. [Abstract]
- Biomed Pharmacother. 2022 Sep:153:113328. [Abstract]
- Cell Rep. 2025 Aug 21;44(9):116186. [Abstract]
- Plant Physiol. 2023 Jul 3;192(3):2507-2522. [Abstract]
- J Cell Biol. 2025 Oct 6;224(10):e202503166. [Abstract]
- Mol Med. 2024 Feb 1;30(1):17. [Abstract]
- Commun Biol. 2025 Feb 25;8(1):304. [Abstract]
- J Virol. 2023 Dec 21;97(12):e0133823. [Abstract]
- J Cancer. 2021 Jun 11;12(16):4819-4829. [Abstract]
- Seoul National University. 2025.
- bioRxiv. 2025 Sep 30.
- Res Sq. 2024 Oct 17.
- bioRxiv. 2024 Apr 26.
- bioRxiv. 2023 Mar 24.
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
Cell Imaging/Staining
-
WB
-
WB
All Antibiotic Isoforms
More
Biological Activity
|
Macrolide |
Concanamycin A can come from S. diastatochromogenes, as a microbial metabolite with immunomodulatory activity[1].
Concanamycin A (100 nM; 0-20 h) results DNA fragmentation in CD4+ and selectively induces CD8+ T cells rapid cell death between normal and the immunized mice source, while CD8+ population in mice immunized is more sensitive[2].
Concanamycin A (3-50 nM; 16 h) inhibits LPS-induced NO production in elicited peritoneal macrophages, but (25 nM; 7 h) doesn’t inhibit LPS-induced TNF-α production[3].
Concanamycin A (0.01 nM-1 nM) inhibits the acidification of rat liver lysosomes (IC50 =0.061 nM), and inhibits oleate incorporation into cholesteryl ester (IC50 =14 nM)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CD8+ cytotoxic T lymphocytes (CTLs)
-
Concentration:100 nM
-
Incubation Time:0, 4, 8, 12, 16, 20 hours
-
Result:Induced rapid cell death instead of apoptosis at 20 h, without observed condensed nuclei.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wild type mice[5]
-
Dosage:15 mg/kg
-
Administration:Intravenous injection 0, 10 or 24 h prior to sacrifice
-
Result:Resulted significant liver injury as demonstrated by serum transaminase levels, inflammatory cell infiltrate, hepatocyte apoptosis, and expression of several cytokines including interleukin 4 (IL4) and interferon gamma (IFNγ) at 10 h and 24 h following administration.
Chemical Information
-
CAS No. 80890-47-7
-
Appearance Solid
-
Molecular Weight 866.09
-
Formula C46H75NO14
-
Color White to off-white
-
SMILES
C[C@H]([C@@](C[C@H]1O[C@@](O[C@H](C)[C@H]2OC(N)=O)([H])C[C@H]2O)(O[C@H](/C=C/C)[C@H]1C)O)[C@H](O)[C@@H]([C@](OC(/C(OC)=C/C(C)=C/[C@H]([C@@H](O)[C@H]3CC)C)=O)([H])[C@H](/C=C/C=C(C[C@H]([C@@H]3O)C)/C)OC)C
-
Synonyms
Antibiotic X 4357B; Folimycin; X 4357B
-
Structure Classification
-
Initial Source
Streptomyces diastatochromogenes S-45
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (28)
-
Journal Impact Factor
-
Most Recent
-
Nat Nanotechnol
2025 Feb;20(2):296-302. PMID: 39468359
Concanamycin A purchased from MedChemExpress. Usage Cited in: Nat Nanotechnol. 2025 Feb;20(2):296-302. [Abstract]
EGFR protein degradation evaluation in MDA-MB-231 cells after treatment with 500 nM NTZ-NPs together with CQ, Baf and Concanamycin A (ConA, 10 nM) for 24 h. Note that for the inhibitors, solvent dimethylsulfoxide (DMSO) represents the control group.
-
Cell Res
A single small molecule-based human embryo model reveals V-ATPase requirement in mammalian blastocyst cavitation. [Abstract]2026 Jul;36(7):475-498. PMID: 41936702 -
Mol Cell
2025 Sep 4;85(17):3333-3342.e4. PMID: 40858109
Concanamycin A purchased from MedChemExpress. Usage Cited in: Mol Cell. 2025 Sep 4;85(17):3333-3342.e4. [Abstract]
Cell death analysis of GPX4 KO HT1080 cells treated with 50 μM deferoxamine (DFO), 2 μM Lip-1, 100 nM BafA1, 100 nM Concanamycin A (ConA), in the absence or presence of 2 μM Trolox as indicated.
Concanamycin A purchased from MedChemExpress. Usage Cited in: Mol Cell. 2025 Sep 4;85(17):3333-3342.e4. [Abstract]
Concanamycin A (ConA; 100 nM; 6 h, a lysosomal inhibitor) prevented lipid peroxidation induced by cysteine deficiency in HT1080 cells.
-
Nat Commun
2025 Jul 18;16(1):6621. PMID: 40681515
Concanamycin A purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 18;16(1):6621. [Abstract]
Pretreatment of Concanamycin A (ConcA, 1 μM; 10 min) inhibited the translocation of GFP-ATG8a to the tonoplast. ConcA was added 10 min prior to monensin treatment. Scale bar, 20 μm.
Concanamycin A purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 18;16(1):6621. [Abstract]
Concanamycin A (ConcA, 1 μM; 10 min) resulted in a significant reduction in the lipidation form of ATG8 following Monensin (20 μM; 1 h) treatment in mammalian cells.
-
Autophagy
The Valsa mali effector Vm1G-1794 protects the aggregated MdEF-Tu from autophagic degradation to promote infection in apple. [Abstract]2023 Jun;19(6):1745-1763. PMID: 36449354 -
Adv Sci (Weinh)
ERAD Component MoHrd3 Facilitates Pathogenicity and Establishes a Direct Regulation on Autophagy in Magnaporthe Oryzae. [Abstract]2026 Apr;13(24):e20627. PMID: 41725610 -
Adv Sci (Weinh)
OTUD6A in Airway Epithelial Cells Exacerbates Allergic Asthma by Promoting Airway Inflammation and Airway Remodeling Through Deubiquitination of hResistin/mRELMα. [Abstract]2026 Jan 20:e16355. PMID: 41560298 -
Adv Sci (Weinh)
CCDC41 Drives Oocyte Meiotic Progression by Promoting Rab11a/Rab7-Positive Vesicle Fusion with Target Membranes. [Abstract]2025 Dec 2:e04665. PMID: 41331237 -
Nat Plants
An apoplastic fungal effector disrupts N-glycosylation of ZmLecRK1, inducing its degradation to suppress disease resistance in maize. [Abstract]2025 Sep 12. PMID: 40940425 -
Biomaterials
2025 Dec 18:329:123925. PMID: 41453350 -
Sci Adv
A noncanonical function of SKP1 regulates the switch between autophagy and unconventional secretion. [Abstract]2023 Oct 13;9(41):eadh1134. PMID: 37831778 -
Cell Death Dis
2023 Aug 29;14(8):571. PMID: 37640723 -
Dev Cell
Ferroptosis induces heterogeneous death profiles that are controlled by lysosome rupture. [Abstract]2026 Feb 17:S1534-5807(26)00037-7. PMID: 41709461 -
Dev Cell
PIF4 controls autophagy during hypocotyl response to elevated ambient temperatures via ArpC5 in Arabidopsis. [Abstract]2025 Jul 9:S1534-5807(25)00402-2. PMID: 40669463 -
Free Radic Biol Med
Glucose deprivation-restoration induces labile iron overload and ferroptosis in renal tubules through V-ATPase-mTOR axis-mediated ferritinophagy and iron release by TPC2. [Abstract]2025 Aug 16:236:204-219. PMID: 40379157 -
Biomed Pharmacother
Lysosomal sequestration of weak base drugs, lysosomal biogenesis, and cell cycle alteration. [Abstract]2022 Sep:153:113328. PMID: 35785701 -
Cell Rep
TCF25 serves as a nutrient sensor to orchestrate metabolic adaptation and cell death by enhancing lysosomal acidification under glucose starvation. [Abstract]2025 Aug 21;44(9):116186. PMID: 40844875 -
Plant Physiol
2023 Jul 3;192(3):2507-2522. PMID: 36946197 -
J Cell Biol
2025 Oct 6;224(10):e202503166. PMID: 40923996 -
Mol Med
2024 Feb 1;30(1):17. PMID: 38302880 -
Commun Biol
Measuring pH in insulin secretory granules by phasor-based fluorescence lifetime imaging of a genetically encoded sensor. [Abstract]2025 Feb 25;8(1):304. PMID: 40000885 -
J Virol
2023 Dec 21;97(12):e0133823. PMID: 38009916 -
J Cancer
Upregulation of V-ATPase by STAT3 Activation Promotes Anoikis Resistance and Tumor Metastasis. [Abstract]2021 Jun 11;12(16):4819-4829. PMID: 34234852 -
-
-
-
-
Solvent & Solubility
DMSO : ≥ 10 mg/mL (11.55 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (421 KB)
- English - EN (421 KB)
- Français - FR (421 KB)
- Deutsch - DE (421 KB)
- Norwegian - NO (421 KB)
- Español - ES (421 KB)
- Swedish - SV (421 KB)
- Italian - IT (421 KB)
- Portuguese - PT (421 KB)
-
Handling Instructions (2659 KB)
References
[1]. Vaněk, Z., et al. Immunomodulators isolated from microorganisms. Folia Microbiol. 1991. 36:99–111.
[2]. Togashi K, et al. Concanamycin A, a vacuolar type H(+)-ATPase inhibitor, induces cell death in activated CD8(+) CTL. Cytotechnology. 1997 Nov;25(1-3):127-35. [Content Brief]
[3]. Eswarappa SM, et al. Folimycin (concanamycin A) inhibits LPS-induced nitric oxide production and reduces surface localization of TLR4 in murine macrophages. Innate Immun. 2008 Feb;14(1):13-24. [Content Brief]
[4]. Hines IN, et al. Impaired T cell-mediated hepatitis in peroxisome proliferator activated receptor alpha (PPARα)-deficient mice. Biol Res. 2018 Feb 15;51(1):5. [Content Brief]
[5]. Woo JT, et al. Isolation, characterization and biological activities of concanamycins as inhibitors of lysosomal acidification. J Antibiot (Tokyo). 1992 Jul;45(7):1108-16. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.1546 mL | 5.7731 mL | 11.5461 mL | 28.8654 mL |
| 5 mM | 0.2309 mL | 1.1546 mL | 2.3092 mL | 5.7731 mL | |
| 10 mM | 0.1155 mL | 0.5773 mL | 1.1546 mL | 2.8865 mL |